The present invention provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, comprising administering to the subject a therapeutically effective amount, of an aromatic-cationic peptide represented by the formula D-Arg-2',6'-Dmt-Lys-Phe-NH2 (SS-31) or Phe-D-Arg-Phe-Lys-NH2 (SS-20). The present invention provides methods of preventing or treating ophthalmic diseases or conditions such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy.To he accompanied, when published, by Figure 1 of the drawings.